05 sep: Lønstigninger er urealistiske
08 sep: Boligfesten er slut
07-09-2006 11:15:00

STRATEC raises sales and earnings forecast for 2008 to 2010

Birkenfeld, September 7, 2006

STRATEC Biomedical Systems AG today published an ad-hoc announcement

(statutory company announcement) with its sales and earnings forecast

for the 2006 and 2007 financial years. Pursuant to this announcement,

the company assumes that it will be possible to increase its sales

for 2006 to between Euro 65 million and Euro 68 million (sales

corridor) and for 2007 to between Euro 75 million and Euro 78 million

(sales corridor) and to increase its earnings before tax (EBT) to

between Euro 10.5 million and Euro 11 million in 2006 (earnings

corridor) and to between Euro 14 million and Euro 15 million in 2007

(earnings corridor).

In view of the considerable increase in the basis for the 2007

financial year, based on its current planning the company expects to

achieve an annual average growth rate (CAGR) of more than 11% in the

case of sales and of more than 16% for earnings before tax (EBT) from

2008 up to and including 2010.

As a result of the basis effect (higher basis in 2007) and the

shifting of the period under consideration by one year from 2008 the

average annual growth rate (CAGR) for our key sales and earnings

figures is lower in percentage terms, yet higher in absolute terms,

in the long-term forecast (for 2008 to 2010) than in the forecast

published in December 2005 (for 2007 to 2009). Assuming that the

targets stated in our long-term forecast are met, the average annual

growth rate (CAGR) reported by the STRATEC Group for the financial

years from 2000 to 2010 would amount to more than 25% in the case of

sales and to more than 34% in the case of earnings before tax (EBT).

The forecast for 2008 to 2010 takes only limited account of the

conclusion of outstanding new development and supply agreements for

new analyzer system families with existing and new customers.

The new budget figures are considerably higher than the internal

budget targets most recently forecast in December 2005. These

forecast that the sales for the 2006 financial year would increase to

Euro 55 million to Euro 59 million (sales corridor) and that earnings

before tax (EBT) would rise to Euro 8.3 million to Euro 9.2 million

(earnings corridor). An average annual growth rate (CAGR) of more

than 15% in the case of sales and of more than 22% for earnings

before tax (EBT) was forecast for the subsequent 2007 to 2009

financial years.

The annual average growth (CAGR) reported for the financial years

from 2000 up to and including 2005 amounted to more than 32% in terms

of sales and to more than 40% in the case of earnings before tax

(EBT).

About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de)

designs and manufactures fully automated systems for its partners in

the fields of clinical diagnostics and biotechnology. These partners

market such systems, in general together with their own reagents, to

laboratories and research institutes around the world. The company

develops its products on the basis of its own patented technologies.

Shares in the company (SIN: 728900 / ISIN: DE0007289001) are traded

in the Prime Standard segment of the Frankfurt Stock Exchange, in the

Gate-M trading segment of the Stuttgart Stock Exchange and on other

exchanges.

The STRATEC Group comprises the listed holding company "STRATEC

Biomedical Systems AG", as well as the subsidiaries "STRATEC NewGen",

"Robion" and "Sanguin".

Further information can be obtained from:

STRATEC Biomedical Systems AG

André Loy, Investor Relations

Gewerbestrasse 37, 75217 Birkenfeld

Germany

Tel: +49 7082 7916-190

Fax: +49 7082 7916-999

E-Mail: ir@stratec-biomedical.de

--- End of Message ---

WKN: 728900; ISIN: DE0007289001;

Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Gate-M in

Börse Stuttgart,

Freiverkehr in Börse Berlin Bremen, Freiverkehr in Bayerische Börse

München,

Freiverkehr in Börse Düsseldorf;

Copyright © Hugin ASA . All rights reserved.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
27 sep
OMXCPI
Hvad har virket? Hvad har jeg lært og forbedret? Og hvad har jeg lært (dyrt) at holde mig fra?   Eft..
48
24 sep
VWS
  Igår holdt præsident Obama en tale ved UN Climate Summit i New York.     Talen var stort set ikke..
21
23 sep
GEN
Hanfrank12 er ikke helt sikker på jeg forstår dit første afsnit, men måske vi er enige og så alligev..
21
25 sep
YHOO
Nej jeg har nu lykønsket ham mange gange med hans performance. Det er for mig at se både flot og isæ..
16
23 sep
FING-B
Bigmammas..(21.52)..   Forkert....   XO.. / 117 andre alias har SELV udskrevet sig fra debatten via ..
16
23 sep
VWS
Jeg synes det er ok du spørger, men du skal alligevel finde ud af substansen selv - når du måske har..
16
25 sep
VWS
Vestas kunde First Wind   http://renews.biz/76379/first-wind-reaches-new-heights/   First Wind vælge..
15
27 sep
VELO
Hej WWW   Her kommer lidt mere "nørd"tænkning, som vi ikke har drøftet før i Veloxisdebatten.   Den ..
14
29 sep
VELO
Jeg kan anbefale alle Veloxis-interesserede at kigge de ældre årsregnskaber igennem - naturligvis is..
13
26 sep
VWS
Jeg synes det lyder som en meget passende beskyldning Mif kommer med, et eller andet er der sku galt..
13

Vestas får aftale med svenske Eolus om 23 MW

29-09-2014 16:22:43
Vestas skal levere syv vindmøller af modellen V126 ifølge en aftale med svenske Eolus Vind, lyder det i en meddelelse fra Eolus.Møllerne, der samlet dækker 23,1..

Vind: Holland udpeger tre zoner til havmølleparker

29-09-2014 14:15:02
Holland har revideret sin strategi for opførelse af havvindmølleparker og udpeget tre havområder, hvor der frem til udgangen af 2020 planlægges opført møller me..

Aktier/åbning: C20 åbner stort set uændret

29-09-2014 09:18:49
Det danske aktiemarked er mandag morgen startet ud med et marginalt fald, hvor især ISS og Coloplast stjæler opmærksomheden. Det danske eliteindeks C20 er åbnet..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Geopoltik og uro i Asien giver nervøsitet
2
Torm modtager konkret forslag til restrukturering - NY
3
Novo's fedmemedicin kræver ja fra USA's arbejdsgivere - avis
4
Mærsk-skib støder sammen med konkurrent i Suezkanalen
5
Mærsk/Nykredit: Sænker anbefaling efter kursridt
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
30. september 2014 07:57:12
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140925.1 - EUROWEB2 - 2014-09-30 07:57:12 - 2014-09-30 07:57:12 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x